ATROPHIC PAPULOSIS

By Gary M. White, MD

Dego's Disease aka Atrophic Papulosis


Also known as Dego's disease, atrophic papulosis (AP) is an occlusive vasculopathy that presents as porcelain white areas. There is a benign cutaneous form and a malignant systemic (and usually fatal) form. Some patients have been found to have abnormalities of the fibrinolytic system or of their platelets. Positive antiphospholipid antibodies have been found.   Multiple members of one family were reported affected in a pattern suggestive of autosomal dominant inheritance.

Clinical

Erythematous papules on the trunk and proximal extremities which develop into atrophic, white, porcelain-centered lesions in a young- to middle-aged man are characteristic. A wedge-shaped area of necrosis is seen histologically.

In one study of 39 patients [British J Dermatology Jan 2014], the mean age of onset was 35 years. Nine percent of patients reported familial occurrence. Extra-cutaneous (systemic) signs were recorded in 29% of the patients, whereas the median time for development of systemic manifestations was 1 year after the occurrence of cutaneous lesions. Seventy-three percent of the patients with systemic manifestations died (e.g. intestinal perforation), while none of the patients with only cutaneous disease had a lethal outcome. The cumulative 5-year survival rate in patients with systemic disease was 54·5%.

Malignant Form

The GIT is the most commonly involved internal organ, especially the small intestine. Perforation and perotinitis are the most common causes of death in MAP. Central or peripheral nervous system involvement may cause significant morbidity or mortality through cerebral infarction. Many other organs may be involved.   

Differential Diagnosis

Porcelain-white centered lesions have been described with antiphospholipid syndrome as well as various connective tissue diseases, e.g., systemic lupus erythematosis [Ann Dermatol. 2017 Apr;29(2):215-218].

Treatment

No reliable therapy currently exists. Eculizumab and treprostinil are being investigated as possible treatment options with some success. Eculizumab, a monoclonal antibody that binds C5 complement, has led to dramatic responses in a small number of patients, possibly because of antiapoptotic endothelial effects.

One patient with abnormality of platelets responded to ASA and dipyridamole. A case of malignant atrophic papulosis was successfully treated with nicotine patches [Br J Dermatol. 2003;149:660-2]. Heparin has been helpful in acutely ill patients. ASA alone (e.g. 300 mg/day) has been reported anecdotally effective in disease limited to the skin [BJD 1998;139;708].

References

DermatologicaSinica June 2014;32, Issue 2, Pages 131–132

RegionalDerm

Homepage | FAQs | Use of Images | Contact Dr. White


It is not the intention of RegionalDerm.com to provide specific medical advice, diagnosis or treatment. RegionalDerm.com only intends to provide users with information regarding various medical conditions for educational purposes and will not provide specific medical advice. Information on RegionalDerm.com is not intended as a substitute for seeking medical treatment and you should always seek the advice of a qualified healthcare provider for diagnosis and for answers to your individual questions. Information contained on RegionalDerm.com should never cause you to disregard professional medical advice or delay seeking treatment. If you live in the United States and believe you are having a medical emergency call 911 immediately.